Report Overview

The Global swine vaccines market Market size is expected to be worth around USD 2.58 million by 2032 from USD 2 million in 2023, growing at a CAGR of 4.20% during the forecast period from 2023 to 2032.

Global food security, agricultural countries, as well as local and international businesses all depend on swine production. The spread of contagious diseases affects the health, stability, and productivity of the global pig industry. According to forecasts, this market opportunity is expected to grow due to the increasing number of diseases in the swine. Porcine Parvovirus, also known as PPV, is a reproductive condition that affects most pig farms worldwide. Porcine Reproductive and Respiratory Syndrome is still a prevalent disease in pig farms. This causes economic loss through its adverse effects on reproduction and market growth key factors, as well as clinical illness.

Global Swine Vaccines Market Scope:

Product Analysis

In terms of ‘Product’, the Inactivated Vaccines segment dominated this global market size estimation, with a 37.1% revenue share in 2021. This market segmentation and product launches are due to low cost, ease of availability, minimal risk, and severity of revert reactions of dead viruses, as well as improvements made by key players. PROGRESS and PARVOVAX are inactivated vaccines for porcine parvovirus.

From 2023 to 2032, the ‘Recombinant Vaccine’ segment is expected to index the highest CAGR. Because recombinants may contain multiple gene inserts, these vaccines will be able to aid against several virus strains. IngelvacCircoFLEX is a recombinant vaccine from Boehringer Ingelheim International GmbH. This vaccine contains PCV 2 and Porcine Circovirus Type-2.

Type Analysis

With respect to ‘Type’, this global market was dominated by the ‘Porcine Circovirus Type-2’ (PCV2) segment, which had a market share greater than 14.9% in 2021. PCV2 is a rapidly mutating virus of single-stranded DNA (ssDNA) and can be transmitted by direct contact with infected pigs. PCV2 is an infectious agent that has a major player impact on pig productivity worldwide, with its presence in India, China, Malaysia, and Thailand. The ‘PCV2’ segment is expected to account for the largest market share over the forecast period.

Over the projected timeline, the ‘Foot & Mouth Disease’ segment is anticipated to experience the second-fastest CAGR. Foot-and-mouth disease, which affects swine, is a serious infection that has an effect on both animal husbandry and food safety, as well as the domestic and international trade in animal goods. It results in societal problems and economic losses. Any pig can contract foot-and-mouth disease. The disease can be prevented by routine vaccines. Since the virus is widespread throughout the world, it is also possible to reintroduce it. This supports the market and gives a detailed analysis of expansion prospects as a whole.

Key Market Segments

Product

• Inactivated Vaccines
• Attenuated Live Vaccines
• DNA Vaccines
• Subunit Vaccines
• Recombinant Vaccines

Type

• Swine Influenza
• Porcine Parvovirus
• Classical Swine Fever
• Porcilis PCV M.Hyo
• Porcine Circovirus Type-2
• PRRS
• Actinobacillus Pleuropneumonia (APP)
• Pseudorabies
• Foot & Mouth Disease
• PEDV
• Others

Market Dynamics

Boehringer Ingelheim received authorization from EMA to use ReprocycParvoFLEX in October 2019. This industry segment is the first subunit porcine parvovirus vaccination to guard against transplacental infection in swine fetuses. The establishment of a pig vaccination program supports the prevention of infectious diseases at all developmental stages. Companies focus on providing vaccination services to properly use swine shots. This is a win-win situation for farmers, whether they are managing bacteria or viruses.

HIPRA, a biotech pharmaceutical company, provides a wide range of services to suit these needs. HIPRA link vaccination is an APP developed by HIPRA that records all data from smart devices (Hipraspray/Hiradermic and Hipraject). It allows users to monitor, control, and analyze their own vaccination activity. This app can be used for swine and poultry vaccines. This is expected to further fuel this market growth trajectory.

The COVID-19 pandemic has had an important impact on the pharmaceutical market largest share. This global threat prompted the pharmaceutical industry trend to expand its research at a remarkable pace. Boehringer Ingelheim Animal Health Business’ R&D unit was renamed Animal Health Global Innovation. The new structure is based on a system-centered R&D approach and a disease-centered R&D approach. These industry experts allow the company’s ability to offer innovative veterinary treatments as well as preventive therapies.

A surge in the demand for animal proteins and the growing preference for low-fat, high-protein diets have led to an increase in pork consumption around the world. The world’s population is expected to increase to 9,800 million by 2050. This makes animal health essential in order to ensure animal welfare and a worldwide supply of protein. This industry segment will likely increase vaccine demand customization in order to protect animals from disease. This customer demand is being further boosted by the current trend toward antibiotic-free manufacturing.

Regional Analysis

The Asia Pacific accounted for the largest revenue share at more than 45.4% in 2021. This region is projected to experience the fastest CAGR over the forecast period. In middle-income countries of the region, especially in Southeast Asia, tend to consume more meat. However, in this region, there is also an increase in epidemic diseases such as Classical Swine Fever. India suffers a significant loss each year due to CSF. India’s government has been more concerned with developing vaccines. For example, ICAR India Veterinary Research Institute introduced a locally developed vaccine for managing CSF in February 2020. The cost is only ₹2 per dose.

North America accounted for a significant revenue share in 2021. This region’s rapid market growth can be attributed to its well-established veterinary health infrastructure, higher demand customization for animal protein, a highly structured farming framework, as well as increased animal health expenditures. Canada and the United States have well-developed healthcare systems and the presence of a number of key players. Pharmgate Animal Health, for example, announced PRRSGard in September 2020. This recombinant chimeric vaccination against Porcine Reproductive and Respiratory Syndrome is largely available in the U.S. Market.

Key Regions and Countries Covered іn This Rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share Analysis

This industry experts is highly competitive with several small and large-scale manufacturers. These companies are actively involved in strategic initiatives to increase market penetration. Algenex SL announced that it had signed an international licensing arrangement for the development of a CrisBio-based vaccine. This agreement was in place in February 2021.

The vaccine will be created and produced using CrisBio, a secured Baculovirus Vector-Mediated Expression Platform that is patented by Algenex. Insects are used by CrisBio to create bioreactors that can be used only once. The China Ministry of Agriculture and Rural Affairs has granted Boehringer Ingelheim a New Veterinary Drug Registry Certificate for the Ingelvac CSF Multi-Use Vaccine. This CSF vaccination was created for the first time by Chinese research organizations and global companies.

Key Market Players

Listed are a few major players in the global market for swine vaccines:

• Merck Animal Health
• Zoetis
• Ceva
• Elanco
• Boehringer Ingelheim GmbH
• Biogenesis Bago SA
• Indian Immunologicals Ltd.
• KM Biologics
• Phibro Animal Health
• MERCK & CO.
• Other Key Players